Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17344112 | 1.00 | USP2 (0.60) | USP2SMN1; SMN2HPGDEPHX2CYP1A2 | |
| SCHEMBL8874348 | 1.00 | USP2 (0.60) | USP2SMN1; SMN2HPGDEPHX2CYP1A2 | |
| Hydrochloric Acid SCHEMBL28702538 | 0.98 | USP2 (0.58) | USP2SMN1; SMN2HPGDEPHX2CYP1A2 | |
| SCHEMBL17271528 | 0.94 | USP2 (0.55) | USP2SMN1; SMN2HPGDEPHX2CYP1A2 | |
| SCHEMBL3958092 | 0.94 | USP2 (0.55) | USP2SMN1; SMN2HPGDEPHX2CYP1A2 | |
| SCHEMBL2740925 | 0.92 | MEN1 (0.54) | USP2SMN1; SMN2HPGDEPHX2MEN1 | |
| SCHEMBL2789172 | 0.92 | USP2 (0.53) | USP2SMN1; SMN2HPGDEPHX2CYP1A2 | |
| SCHEMBL18294 | 0.91 | USP2 (0.69) | USP2SMN1; SMN2HPGDEPHX2MEN1 | |
| SCHEMBL698803 | 0.91 | USP2 (0.69) | USP2SMN1; SMN2HPGDEPHX2MEN1 | |
| SCHEMBL21779943 | 0.89 | USP2 (0.53) | USP2SMN1; SMN2HPGDEPHX2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1011 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120079243-A | Heavy metal enriched block polymer nanofiltration membrane and preparation method thereof | 浙江工业大学 | 2025-06-03 | — | — | CN | claimed |
| US-9227967-B2 | Inhibitor compounds of semicarbazide-sensitive amine oxidases | PROXIMAGEN LIMITED (GB) | 2016-01-05 | — | — | US | claimed |
| US-20130102587-A1 | New Enzyme Inhibitor Compounds | PROXIMAGEN LIMITED (GB) | 2013-04-25 | — | — | US | claimed |
| EP-2547677-A2 | INHIBITORS OF SEMICARABAZIDE - SENSITIVE AMINE OXIDASE | Proximagen Limited (GB) | 2013-01-23 | — | — | EP | claimed |
| WO-2011113798-A2 | NEW ENZYME INHIBITOR COMPOUNDS | PROXIMAGEN LIMITED (GB) | 2011-09-22 | — | — | WO | claimed |
| EP-4596535-A1 | DRUG FOR TREATING HUMAN TUMOR BY ERF3A TARGETED PROTEIN DEGRADATION MECHANISM | Suzhou Degen Bio-Medical Co, Ltd. (CN) | 2025-08-06 | — | — | EP | disclosed |
| US-20250213701-A1 | MEDICAMENT FOR TREATING HUMAN TUMOR BASED ON ERF3A-TARGETING PROTEOLYSIS MECHANISM | SUZHOU DEGEN BIO-MEDICAL CO., LTD. (CN) | 2025-07-03 | — | — | US | disclosed |
| CN-120079243-A | Heavy metal enriched block polymer nanofiltration membrane and preparation method thereof | 浙江工业大学 | 2025-06-03 | — | — | CN | disclosed |
| CN-115745907-B | Antibacterial and antitumor synergist and synthetic method and application thereof | 苏州大学 | 2025-05-16 | — | — | CN | disclosed |
| WO-2025085848-A1 | ANTIBACTERIAL COMPOUNDS | ARREPATH, INC. (US) | 2025-04-24 | — | — | WO | disclosed |
| US-20250122192-A1 | 5-PYRIMIDINECARBOXAMIDE DERIVATIVES AND METHODS OF USING THE SAME | RGENTA THERAPEUTICS, INC. | 2025-04-17 | — | — | US | disclosed |
| CN-119613403-A | 4-Indolinyl substituted pyrido [3,2-d ] pyrimidine compounds and application thereof | 沈阳药科大学 | 2025-03-14 | — | — | CN | disclosed |
| CN-1301253-A | Carboxy substituted carboxamide derivatives as tachykinin receptor antagonists | AVENTIS PHARMACEUTICAL INC (US) | 2001-06-27 | — | — | CN | disclosed |
| WO-2000078728-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THESE COMPOUNDS | NEUROSEARCH A/S (DK) | 2000-12-28 | — | — | WO | disclosed |
| WO-2000076984-A2 | NOVEL COMPOUNDS, THEIR USE AND PREPARATION | BIOVITRUM AB (SE) | 2000-12-21 | — | — | WO | disclosed |
| US-5532354-A | ANTIBIOTICS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-07-02 | — | — | US | disclosed |
| US-5401734-A | MICROBIOCIDES | FUJISAWA PHAMACEUTICAL CO., LTD. (JP) | 1995-03-28 | — | — | US | disclosed |
| US-5244890-A | Treatment of infectious diseases | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-09-14 | — | — | US | disclosed |
| EP-0345671-A2 | Cephem compounds and processes for preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1989-12-13 | — | — | EP | disclosed |
| EP-0192176-A2 | Cephalosporins, process for their preparation and their use in medicaments | BAYER AG (DE) | 1986-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122192-A1 | 5-PYRIMIDINECARBOXAMIDE DERIVATIVES AND METHODS OF USING THE SAME | RTCB, NSUN2, PRPF19 | USP2 3389/4885SMN1; SMN2 425/4885HPGD 799/4885 |
| US-20130102587-A1 | New Enzyme Inhibitor Compounds | SERPINB1, SSB, NFKBIA | USP2 1975/4885SMN1; SMN2 2470/4885HPGD 74/4885 |
| US-20250213701-A1 | MEDICAMENT FOR TREATING HUMAN TUMOR BASED ON ERF3A-TARGETING PROTEOLYSIS MECHANISM | XIAP, TP53, UBE3A | USP2 198/4885SMN1; SMN2 3863/4885HPGD 4216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.